Is CVE-2020-16222 actively exploited?

CVE-2020-16222 has no public evidence of in-the-wild exploitation as of 2026-02-23.

What is the CVSS score for CVE-2020-16222?

CVE-2020-16222 has a CVSS score of 8.8 (HIGH severity). Vector: CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H.

How do I patch CVE-2020-16222?

Patch guidance is available from philips security advisories. CVEDatabase generates AI-assisted remediation guidance on demand for CVE-2020-16222.

Fix CVE-2020-16222 - HIGH | CVEDatabase.com

Q: Which products are affected by CVE-2020-16222?

4 products: philips patient information center ix, philips patient information center ix, philips patient information center ix, philips performancebridge focal point.

Description

In Patient Information Center iX (PICiX) Version B.02, C.02, C.03, and PerformanceBridge Focal Point Version A.01, when an actor claims to have a given identity, the software does not prove or insufficiently proves the claim is correct.

CVSS Metrics

Vector: CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Attack Vector: adjacent network
Complexity: low
Privileges: none
User Action: none
Scope: unchanged
Confidentiality: high
Integrity: high
Availability: high
Weaknesses: CWE-287 · Improper Authentication

Metadata

Primary Vendor: PHILIPS
Published: 9/11/2020
Last Modified: 2/23/2026
Source: NIST NVD
Note: Verify all details with official vendor sources before applying patches.

Affected Products

philips : patient_information_center_ixphilips : patient_information_center_ixphilips : patient_information_center_ixphilips : performancebridge_focal_point

Remediation Guidance

Executive Summary

Cite this page

CVE-2020-16222. CVEDatabase.com. Retrieved 1 May 2026. https://cvedatabase.com/cve/CVE-2020-16222

View on NIST NVD

CVE-2020-16222 vulnerability